UTI Risk: Jardiance vs Forxiga
Based on the most recent and highest quality evidence, both empagliflozin (Jardiance) and dapagliflozin (Forxiga) have comparable UTI risks overall, but empagliflozin (Jardiance) appears to have a slightly lower UTI risk, particularly at higher doses and with longer treatment duration.
Key Evidence from FDA Drug Labels
The Jardiance (empagliflozin) FDA label 11 reports UTI incidence data from pooled placebo-controlled trials:
- Female patients: Placebo 16.6%, Jardiance 10 mg 18.4%, Jardiance 25 mg 17.0%
- Male patients: Placebo 3.2%, Jardiance 10 mg 3.6%, Jardiance 25 mg 4.1%
- Treatment discontinuation due to UTI: 0.1-0.2% across all Jardiance doses
Comparative Research Evidence
Most Recent Head-to-Head Comparison (2026)
A large population-based target trial emulation 2 directly comparing empagliflozin versus dapagliflozin in 86,432 patients found:
- 1-year UTI risk was essentially identical: Empagliflozin 10.3% vs Dapagliflozin 10.6% (RR 0.98,95% CI 0.95-1.01)
- Results remained consistent through 5-year follow-up
- However, empagliflozin showed slightly higher risks of genital tract infections (2.2% vs 2.0%) and phimosis (1.0% vs 0.8%)
Drug-Specific Meta-Analyses
For Dapagliflozin (Forxiga):
- Multiple meta-analyses 345 consistently show dapagliflozin 10 mg is associated with increased UTI risk
- High-dose dapagliflozin (≥10 mg) with treatment >24 weeks: OR 1.27 (95% CI 1.13-1.43) 5
- Dapagliflozin 10 mg vs placebo: RR 1.33 (95% CI 1.10-1.61) 4
For Empagliflozin (Jardiance):
- Recent FAERS database analysis 6 found empagliflozin showed the lowest risk of UTIs among SGLT2 inhibitors (ROR 0.928,95% CI 0.858-1.005)
- Large meta-analysis 7 found no statistically significant increase in UTI risk with SGLT2 inhibitors overall
Clinical Algorithm for Decision-Making
Choose Jardiance (empagliflozin) if:
- Patient has history of recurrent UTIs
- Female patient (higher baseline UTI risk)
- Long-term treatment anticipated (>6 months)
- Patient requires higher SGLT2i doses
Choose Forxiga (dapagliflozin) if:
- Genital infection history is the primary concern (slightly lower risk)
- Lower dose therapy planned (<10 mg)
- Short-term treatment anticipated
Important Clinical Caveats
Risk Factors Requiring Extra Vigilance
Both medications increase UTI risk in patients with:
- Age >60 years (aPR 3.77) 8
- Female sex (aPR 2.92) 8
- History of chronic/recurrent UTIs 11
- Treatment duration ≥4 months (aPR 3.19) 8
Serious UTI Risk
Reassuringly, neither medication increases risk of serious or complicated UTI (pooled RR 0.99,95% CI 0.78-1.27) 7. This is a critical distinction—the excess risk is primarily mild, uncomplicated UTIs.
Genital Infections
While the question focuses on UTI, note that both drugs significantly increase genital mycotic infection risk (3-4 fold increase vs placebo) 11, with empagliflozin showing slightly higher rates than dapagliflozin 2.
Practical Management
When prescribing either medication:
- Screen for UTI history before initiation
- Educate patients about UTI symptoms (dysuria, frequency, urgency)
- Consider prophylactic measures in high-risk patients (adequate hydration, proper hygiene)
- Monitor more closely during first 4-6 months of therapy
- If UTI develops, treat appropriately but continuation of SGLT2i is usually safe unless recurrent infections occur
The absolute difference in UTI risk between these two medications is small (approximately 0.3% at 1 year 2), so the choice should also incorporate their cardiovascular and renal benefits, which are substantial and well-established 9.